Cardiovascular safety of febuxostat and allopurinol in patients with gout: A meta-analysis
Background: Gout is a common disease and is usually treated with uric acid-lowering drugs (the most commonly used of which are febuxostat and allopurinol). However, the cardiovascular safety of febuxostat and allopurinol is still controversial. The purpose of our study is to evaluate the cardiovascu...
Saved in:
Main Authors: | Xudong Guan (Author), Shengzhao Zhang (Author), Jiayan Liu (Author), Fengbo Wu (Author), Lingyan Zhou (Author), Ying Liu (Author), Na Su (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2022-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Cardiovascular safety of febuxostat versus allopurinol among the Asian patients with or without gout: A systematic review and meta‐analysis
by: Jian‐hao Deng, et al.
Published: (2024) -
Hepatic Safety of Febuxostat and Allopurinol for Gout Patients: A Systematic Review of Randomized Controlled Trial
by: Dewi C, et al.
Published: (2023) -
The potential renoprotection of xanthine oxidase inhibitors: Febuxostat versus allopurinol
by: Dong-Ryeol Ryu
Published: (2017) -
Renoprotective effects of febuxostat compared with allopurinol in patients with hyperuricemia: A systematic review and meta-analysis
by: Sollip Kim, et al.
Published: (2017) -
Febuxostat in the management of hyperuricemia and chronic gout: a review
by: Miao Hu, et al.
Published: (2008)